GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Net Income Including Noncontrolling Interests

OptimizeRx (OptimizeRx) Net Income Including Noncontrolling Interests : $-17.57 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

OptimizeRx's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was $-4.14 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was $-17.57 Mil.

OptimizeRx Net Income Including Noncontrolling Interests Historical Data

The historical data trend for OptimizeRx's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Net Income Including Noncontrolling Interests Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.14 -2.21 0.38 -11.44 -17.57

OptimizeRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -6.40 -4.16 -2.87 -4.14

OptimizeRx Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptimizeRx Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

OptimizeRx (OptimizeRx) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
AMWL AUGX AMJT SY TBRG FORA WGS SHCR BEAT VASO GEHC VEEV SOLV TSE:2413 ASX:PME HQY RCM DOCS TXG EVH
Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
Website
https://www.optimizerx.com
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022